As of Thursday close, Clovis Oncology Inc.’s (NASDAQ:CLVS) stock was down -$0.01, moving down -0.61 percent to $1.64. The average number of shares traded per day over the past five days has been 3,128,100 shares. 2 times new highs have been achieved over the past 5 days, with a -$0.1000 fall in that time frame. In the last twenty days, the average volume was 10,762,084, while in the previous 50 days, it was 14,821,884.
Since last month, CLVS stock retreated -24.77%. Shares of the company fell to $1.4500 on 08/02/22, the lowest level in the past month. A 52-week high of $5.24 was reached on 07/08/22 after having rallying from a 52-week low of $0.58. Since the beginning of this year, CLVS’s stock price has dropped by -39.48% or -$1.0700, and marked a new high 3 times. However, the stock has declined by -68.70% since its 52-week high.
Top 5 Cheap Stocks to Own Right Now
While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.
Sign up here to get your free report now. .
Clovis Oncology Inc. (CLVS) last reported insider trading activity 3 days ago on Aug 02. Gross Paul Edward, the See Remarks of the company, disposed of 4,807 shares for $1.46 on Aug 02. It resulted in a $7,024 divestment by the insider. IVERS-READ GILLIAN C sold 3,802 shares at an average price of $1.46 on Aug 02. The insider now owns 283,565 shares following the transaction. On Aug 02, See Remarks Rolfe Lindsey sold 4,330 shares at $1.46 apiece. The transaction was valued at $6,326.
In the three months ended March 30, Clovis Oncology Inc.’s quick ratio stood at 1.40, while its current ratio was 1.50, showing that the company is able to pay off its debt. On the profitability front, the trailing twelve-month gross margin is 73.40% percent. Based on annual data, CLVS earned $109.93 million in gross profit and brought in $148.76 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -67.70%. Return on equity (ROE) for the past 12 months was 101.90%.
According to the earnings report, the company had a lower net income in the recent quarter than it did in the previous quarter. CLVS’s revenue fell -11.09% to $35.97 million during the quarter, while net income inched up to $34.25 million. While analysts expected Clovis Oncology Inc. to report -$0.43 quarterly earnings, the actual figure was -$0.44 per share, beating the consensus estimate by -2.30%. During the quarter, the company generated -$47.88 million in EBITDA. The liabilities of Clovis Oncology Inc. were 754.84 million at the end of its most recent quarter ended March 30, and its total debt was $653.56 million. The value of shareholders’ equity is $143.88 million.
This quick technical analysis looks at Clovis Oncology Inc.’s (CLVS) price momentum. With a historical volatility rate of 100.57%, the RSI 9-day stood at 41.24% on 04 August.
With respect to its five-day moving average, the current Clovis Oncology Inc. price is down by -5.75% percent or -$0.1000. At present, CLVS shares trade -24.42% below its 20-day simple moving average and +3.80% percent above its 100-day simple moving average. However, the stock is currently trading approximately +139.45% above its SMA50 and -60.86% below its SMA200.
Stochastic coefficient K was 19.34% and Stochastic coefficient D was 12.53%, while ATR was 0.2172. Given the Stochastic reading of 24.05% for the 14-day period, the RSI (14) reading has been calculated as 45.46%. As of today, the MACD Oscillator reading stands at -0.0356, while the 14-day reading stands at -0.1250.
Clovis Oncology Inc. downgraded its rating on Clovis Oncology Inc. (NASDAQ: CLVS) to a Neutral in a note to investors on May 06, 2022. The analysts firm previously had a Buy rating on the stock.Clovis Oncology Inc. (CLVS) has been rated Hold by analysts. According to 0 brokerage firms, CLVS is a sell, and 2 firms recommend it is a Hold. There are 1 analyst who say the stock is underweight. A total of 0 analysts rate Clovis Oncology Inc. stock as buy, with 0 recommending it as overweight.
With a median target price of $3.00, the current consensus forecast for the stock is $3.00 – $3.00. Based on these forecasts, analysts predict Clovis Oncology Inc. (CLVS) will achieve an average price target of $3.00.